Medgenics, the developer of technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, reported that its wholly owned subsidiary Medgenics Medical Israel was awarded a government grant of up to NIS 8.1 million (approximately $2.2 million) from the Office of the Chief Scientist in Israel. The grant will be used to cover R&D expenses to support further clinical development of the company’s proprietary tissue-based Biopump platform technology. Medgenics holds offices in San Francisco, California and Misgav, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments